Meeting
2015 ASCO Annual Meeting
Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.
Authors
Jeffrey S. Weber
Moffitt Cancer Center, Tampa, FL
Jeffrey S. Weber , Scott Joseph Antonia , Suzanne Louise Topalian , Dirk Schadendorf , James M. G. Larkin , Mario Sznol , Helen Y Liu , Ian Waxman , Caroline Robert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9018)
DOI
10.1200/jco.2015.33.15_suppl.9018
Abstract #
9018
Poster Bd #
261
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): a single-arm, open-label, multicenter, phase II study (CheckMate 172).
First Author: Paolo Antonio Ascierto
Poster
2017 ASCO Annual Meeting
Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
First Author: David Hogg
Poster
2015 ASCO Annual Meeting
A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).
First Author: Dirk Schadendorf
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini